Advertisement
UK markets close in 1 hour 59 minutes
  • FTSE 100

    8,116.80
    +37.94 (+0.47%)
     
  • FTSE 250

    19,785.09
    +183.11 (+0.93%)
     
  • AIM

    755.19
    +2.07 (+0.27%)
     
  • GBP/EUR

    1.1674
    +0.0018 (+0.15%)
     
  • GBP/USD

    1.2508
    -0.0003 (-0.03%)
     
  • Bitcoin GBP

    50,989.37
    +459.95 (+0.91%)
     
  • CMC Crypto 200

    1,380.38
    -16.15 (-1.16%)
     
  • S&P 500

    5,078.44
    +30.02 (+0.59%)
     
  • DOW

    38,084.94
    -0.86 (-0.00%)
     
  • CRUDE OIL

    84.19
    +0.62 (+0.74%)
     
  • GOLD FUTURES

    2,359.60
    +17.10 (+0.73%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,073.69
    +156.41 (+0.87%)
     
  • CAC 40

    8,056.42
    +39.77 (+0.50%)
     

Tandem Diabetes (TNDM) Looks Good: Stock Adds 6.5% in Session

Tandem Diabetes Care, Inc. TNDM was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $77.34 – $87.74 in the past one-month time frame, witnessed a sharp increase yesterday.

This move came after U.S. Food and Drug Administration (FDA) approved the expansion of pediatric indication for the t:slim X2 insulin pump.

The company has seen one positive estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Tandem Diabetes. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Tandem Diabetes Care, Inc. Price

Tandem Diabetes Care, Inc. Price
Tandem Diabetes Care, Inc. Price

Tandem Diabetes Care, Inc. price | Tandem Diabetes Care, Inc. Quote

ADVERTISEMENT

Tandem Diabetes currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.

A better-ranked stock in the Medical - Instruments industry is ViewRay, Inc. VRAY, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Zacks’ Single Best Pick to Double

From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.

This young company’s gigantic growth was hidden by low-volume trading, then cut short by the coronavirus. But its digital products stand out in a region where the internet economy has tripled since 2015 and looks to triple again by 2025.

Its stock price is already starting to resume its upward arc. The sky’s the limit! And the earlier you get in, the greater your potential gain.

Click Here, See It Free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Tandem Diabetes Care, Inc. (TNDM) : Free Stock Analysis Report
 
ViewRay, Inc. (VRAY) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research